MCP Danish Cancer Society
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/mcp.M800204-MCP200 on August 6, 2008.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
M800204-MCP200v1
7/10/1902    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Glossary
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by VanMeter, A. J.
Right arrow Articles by Espina, V.
PubMed
Right arrow PubMed Citation
Right arrow Articles by VanMeter, A. J.
Right arrow Articles by Espina, V.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Molecular & Cellular Proteomics 7:1902-1924, 2008.
© 2008 by The American Society for Biochemistry and Molecular Biology, Inc.


Research

Laser Capture Microdissection and Protein Microarray Analysis of Human Non-small Cell Lung Cancer

Differential Epidermal Growth Factor Receptor (EGPR) Phosphorylation Events Associated with Mutated EGFR Compared with Wild Type*,S

Amy J. VanMeter{ddagger}, Adrianna S. Rodriguez§, Elise D. Bowman||, Jin Jen**, Curtis C. Harris||, Jianghong Deng{ddagger}, Valerie S. Calvert{ddagger}, Alessandra Silvestri{ddagger},{ddagger}{ddagger}, Claudia Fredolini{ddagger},§§, Vikas Chandhoke{ddagger}, Emanuel F. Petricoin, III{ddagger}, Lance A. Liotta{ddagger} and Virginia Espina{ddagger},¶¶

From the {ddagger} Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia 20110, Laboratories of § Pathology, || Human Carcinogenesis, and ** Population Genetics, NCI, National Institutes of Health, Bethesda, Maryland 20892, {ddagger}{ddagger} Centro di Riferimento Oncologico-Istituto di Ricovero e Cura a Carattere Scientifico, National Cancer Institute, Pordenone Aviano, Italy, and §§ Center for Experimental Research and Medical Studies, University of Turin San Giovanni Battista Hospital, Torino Turin, Italy

Little is known about lung carcinoma epidermal growth factor (EGF) kinase pathway signaling within the context of the tissue microenvironment. We quantitatively profiled the phosphorylation and abundance of signal pathway proteins relevant to the EGF receptor within laser capture microdissected untreated, human non-small cell lung cancer (NSCLC) (n = 25) of known epidermal growth factor receptor (EGFR) tyrosine kinase domain mutation status. We measured six phosphorylation sites on EGFR to evaluate whether EGFR mutation status in vivo was associated with the coordinated phosphorylation of specific multiple phosphorylation sites on the EGFR and downstream proteins. Reverse phase protein array quantitation of NSCLC revealed simultaneous increased phosphorylation of EGFR residues Tyr-1148 (p < 0.044) and Tyr-1068 (p < 0.026) and decreased phosphorylation of EGFR Tyr-1045 (p < 0.002), HER2 Tyr-1248 (p < 0.015), IRS-1 Ser-612 (p < 0.001), and SMAD Ser-465/467 (p < 0.011) across all classes of mutated EGFR patient samples compared with wild type. To explore which subset of correlations was influenced by ligand induction versus an intrinsic phenotype of the EGFR mutants, we profiled the time course of 115 cellular signal proteins for EGF ligand-stimulated (three dosages) NSCLC mutant and wild type cultured cell lines. EGFR mutant cell lines (H1975 L858R) displayed a pattern of EGFR Tyr-1045 and HER2 Tyr-1248 phosphorylation similar to that found in tissue. Persistence of phosphorylation for AKT Ser-473 following ligand stimulation was found for the mutant. These data suggest that a higher proportion of the EGFR mutant carcinoma cells may exhibit activation of the phosphatidylinositol 3-kinase/protein kinase B (AKT)/mammalian target of rapamycin (MTOR) pathway through Tyr-1148 and Tyr-1068 and suppression of IRS-1 Ser-612, altered heterodimerization with ERBB2, reduced response to transforming growth factor β suppression, and reduced ubiquitination/degradation of the EGFR through EGFR Tyr-1045, thus providing a survival advantage. This is the first comparison of multiple, site-specific phosphoproteins with the EGFR tyrosine kinase domain mutation status in vivo.


¶¶ To whom correspondence should be addressed: Center for Applied Proteomics and Molecular Medicine, George Mason University, 10900 University Blvd., MS 1A9, Manassas, VA 20110. Tel.: 703-993-8062; Fax: 703-993-8606; E-mail: vespina{at}gmu.edu


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2008 by the American Society for Biochemistry and Molecular Biology.